Compare TX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TX | QGEN |
|---|---|---|
| Founded | 1961 | 1986 |
| Country | Luxembourg | Netherlands |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.2B |
| IPO Year | 2006 | 1998 |
| Metric | TX | QGEN |
|---|---|---|
| Price | $46.30 | $36.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $37.70 | ★ $45.76 |
| AVG Volume (30 Days) | 557.6K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | 6.31% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.60 | $8.18 |
| Revenue Next Year | $6.66 | $5.71 |
| P/E Ratio | ★ $20.15 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.77 | $32.53 |
| 52 Week High | $51.73 | $57.82 |
| Indicator | TX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 52.91 |
| Support Level | $41.73 | $32.85 |
| Resistance Level | $49.69 | $38.10 |
| Average True Range (ATR) | 1.72 | 0.92 |
| MACD | -0.38 | 0.09 |
| Stochastic Oscillator | 2.16 | 56.44 |
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).